Zonisamide
- 1 May 1999
- Vol. 40 (s5), s23-s29
- https://doi.org/10.1111/j.1528-1157.1999.tb00916.x
Abstract
Zonisamide (ZNS) is a broad-spectrum antiepileptic drug in both animal models of epilepsy and patients with epilepsy. It is effective for both localization-related and generalized epilepsies and appears to be particularly potent in progressive myoclonic epilepsy syndromes. Its pharmokinetic profile is favorable, with a long half-life and low protein binding. However, its insolubility may make the development of a parenteral formulation difficult. Its safety profile is good, although teratogenicity in animal models is of concern. Adult doses of 400-600 mg per day in two doses, with blood levels from 20 to 30 mg/ml, appear to be effective.Keywords
This publication has 31 references indexed in Scilit:
- Formation of 2-sulphamoylacetylphenol from zonisamide under aerobic conditions in rat liver microsomesXenobiotica, 1996
- Drug interactions of zonisamide with phenytoin and sodium valproate: serum concentrations and protein bindingBrain & Development, 1995
- Zonisamide‐Induced Behavior Disorder in Two ChildrenEpilepsia, 1994
- Efficacy and safety of zonisamide: results of a multicenter studyEpilepsy Research, 1993
- Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortexEpilepsy Research, 1992
- Pharmacokinetic Interaction of Zonisamide in Rats. Effect of Other Antiepileptics on Zonisamide.Journal of Pharmacobio-Dynamics, 1992
- Reductive metabolism of the anticonvulsant agent zonisamide, a 1,2-benzisoxazole derivativeXenobiotica, 1992
- Anticonvulsant effects of zonisamide and phenytoin on seizure activity of the feline visual cortexBrain & Development, 1990
- Binding of sulfonamides to erythrocyte proteins and possible drug-drug interaction.CHEMICAL & PHARMACEUTICAL BULLETIN, 1989
- Studies on 3-substituted 1,2-benzisoxazole derivatives. I.CHEMICAL & PHARMACEUTICAL BULLETIN, 1976